Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9517504rdf:typepubmed:Citationlld:pubmed
pubmed-article:9517504lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:9517504lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:9517504lifeskim:mentionsumls-concept:C0023449lld:lifeskim
pubmed-article:9517504lifeskim:mentionsumls-concept:C0017428lld:lifeskim
pubmed-article:9517504lifeskim:mentionsumls-concept:C1521970lld:lifeskim
pubmed-article:9517504lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:9517504lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:9517504lifeskim:mentionsumls-concept:C2348519lld:lifeskim
pubmed-article:9517504pubmed:issue3-4lld:pubmed
pubmed-article:9517504pubmed:dateCreated1998-5-13lld:pubmed
pubmed-article:9517504pubmed:abstractTextThe less differentiated stage (CD10-) of B-lineage acute lymphoblastic leukaemia (ALL) described as preB1-ALL in the GEIL nomenclature, accounts for less than 10% of ALL. It is classically considered to be associated with translocation (4;11)(q21;q23), and to have a poor prognosis. We report an extensive immunophenotypic, genomic and clinical study of a series of 64 preB-1 ALL patients, representing 6.3% of a cohort of consecutive ALLs. The engagement of preB1-ALL cells in the B-lineage was confirmed by their B-lineage score, equal to or higher than 2. In addition, more than 90% of the cases tested showed rearranged IGH genes. Translocation (4;11) was the most frequent karyotypic anomaly seen, but only accounted for 24% of the preB1-ALL cases tested. Expression of the myeloid associated antigen CD15 was also found with high incidence in this subset. Clinical and biological features at presentation showed more significant differences between preB1- and T-ALL than between preB1- and preB2-ALL (CD10+). However, outcome characteristics of the 22 children with preB1-ALL confirmed the worse prognosis of this entity.lld:pubmed
pubmed-article:9517504pubmed:languageenglld:pubmed
pubmed-article:9517504pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:citationSubsetIMlld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9517504pubmed:statusMEDLINElld:pubmed
pubmed-article:9517504pubmed:monthJanlld:pubmed
pubmed-article:9517504pubmed:issn1042-8194lld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:MonconduitMMlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:GarandRRlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:TillyHHlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:LefrancM PMPlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:FalkenrodtAAlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:VannierJ PJPlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:SolaryEElld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:LenormandBBlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:BénéM CMClld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:KandelGGlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:BastardCClld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:FaureG CGClld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:MaynadiéMMlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:CallatM PMPlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:LesesveJ FJFlld:pubmed
pubmed-article:9517504pubmed:authorpubmed-author:ThouretFFlld:pubmed
pubmed-article:9517504pubmed:issnTypePrintlld:pubmed
pubmed-article:9517504pubmed:volume28lld:pubmed
pubmed-article:9517504pubmed:ownerNLMlld:pubmed
pubmed-article:9517504pubmed:authorsCompleteYlld:pubmed
pubmed-article:9517504pubmed:pagination329-42lld:pubmed
pubmed-article:9517504pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:meshHeadingpubmed-meshheading:9517504-...lld:pubmed
pubmed-article:9517504pubmed:year1998lld:pubmed
pubmed-article:9517504pubmed:articleTitlePreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies.lld:pubmed
pubmed-article:9517504pubmed:affiliationLaboratoire Hématologie et Service de Pédiatrie, C.H.U. Charles Nicolle, Rouen, France.lld:pubmed
pubmed-article:9517504pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9517504pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9517504pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:9517504pubmed:publicationTypeMulticenter Studylld:pubmed